Business Wire

PPRO Announces Strategic Investment From JPMorgan Chase & Co., Bringing Total Round to $270 Million

25.3.2021 15:00:00 EET | Business Wire | Press release

Share

PPRO, a leading provider of local payments infrastructure, has announced new investments today from JPMorgan Chase & Co. and Eldridge. The latest investment is an extension of the US $180 million round from Eurazeo Growth, Sprints Capital, and Wellington Management announced just weeks ago.

Leading payment companies rely on PPRO’s infrastructure to accept payments from consumers all over the world. Beyond offering access to a comprehensive payments portfolio, PPRO’s technology and value-added services help them deliver the industry’s best conversion rates to its global customers.

“I’m delighted to welcome JPMorgan Chase and Eldridge to our world-class group of investors as we continue to strengthen and expand our local and alternative payment capabilities,” said Simon Black, CEO of PPRO.

PPRO has experienced rapid growth in the wake of the e-commerce boom, doubling its transaction volumes and increasing its global team by over 60% in 2020. The company’s continued global expansion has led to the development of new strategic partnerships with local payment methods in high-growth markets from Indonesia to Italy.

“Alternative payments adoption is increasing rapidly across the globe. We are proud to become a strategic investor in PPRO as they work on their next phase of growth,” said Sanjay Saraf, Managing Director, Global Head Integrated Payments Group at JPMorgan Chase.

Financial Technology Partners acted as exclusive financial advisor and Noerr as legal advisor to PPRO in the transaction.

About PPRO:
PPRO is the top global provider of local payments infrastructure, powering growth for payment service providers and enterprises with payment platforms.

Companies at the forefront of payments technology leverage PPRO’s unified platform, expert services, and local payment methods to boost sales in over 100 e-commerce markets worldwide. In 2020 alone, PPRO processed over $11 billion for its customers, including companies such as Mollie, PayPal, Worldpay, and many others.

With strategic local payments partnerships and a talented team of over 300 people in every corner of the world, it is the industry’s trusted provider of local payments infrastructure.

PPRO is regulated in the UK by the FCA and in Luxembourg by the CSSF. For more information, please visit www.ppro.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Anna Patrick
anna@mediafrenzyglobal.com
201.704.6311

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting Strengthens Digital Transformation Capabilities with Weexa30.4.2026 16:30:00 EEST | Press release

Andersen Consulting enters into a Collaboration Agreement with Weexa, a global provider of digital transformation, B2B integration, and supply chain digitalization solutions. Headquartered in France, Weexa delivers end-to-end services that help organizations streamline, secure, and scale their digital ecosystems. The firm specializes in B2B data-flow management and digitalization, enabling seamless communication between applications both within and across organizations through technologies such as EDI, APIs, and e-invoicing. Weexa also provides SAP integration and supply chain solutions spanning warehouse and transport management, alongside strategic consulting, project delivery, and third-party application maintenance. Serving organizations across the food, retail, wholesale, logistics, transportation, automotive, healthcare, and media sectors, Weexa supports global businesses in optimizing performance while meeting evolving regulatory and digital-compliance requirements. “Collaborati

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 16:22:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et

Experian Announces Agent Trust to Power Trusted AI Driven Commerce30.4.2026 16:00:00 EEST | Press release

Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430719198/en/ Experian Announces Agent Trust to Power Trusted AI Driven Commerce. As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust addresses this challenge through a new “Know Your Agent” (KYA) framework, extending identity verification into the age of AI. The framework ensures that agent-initiated transactions are grounded in verified consumer identity. “Agen

Meet the AI-powered fan companion: TGR Haas F1 Team RaceMate powered by Infobip30.4.2026 16:00:00 EEST | Press release

Global AI-first cloud communications platform Infobip and TGR Haas F1 team are launching ‘TGR Haas F1 Team RaceMate powered by Infobip’, an AI-powered conversational fan companion on Apple Messages for Business and WhatsApp Business Platform. Always-on and always available, it delivers race intelligence for TGR Haas F1 Team: team race intelligence, grid positions, qualifying outcomes, sprint results, and full session schedules. The AI agent tracks drivers Ollie Bearman and Esteban Ocon with their individual championship standings and performance data in conversational format. The agent draws from a knowledge base covering driver biographies, team history, and circuit data, adapting to each user's knowledge level. Every interaction begins with a schedule check, ensuring fans always know what's happening right now. It proactively surfaces relevant information, suggests next actions, and maintains conversational flow to keep every interaction effortless and engaging. Delivered in short, s

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye